Liquidia Technologies (NASDAQ:LQDA) and Calmare Therapeutics (OTCMKTS:CTTC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.
This is a breakdown of recent ratings and recommmendations for Liquidia Technologies and Calmare Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Liquidia Technologies | 0 | 0 | 1 | 0 | 3.00 |
| Calmare Therapeutics | 0 | 0 | 0 | 0 | N/A |
Liquidia Technologies presently has a consensus target price of $50.00, suggesting a potential upside of 1,401.50%. Given Liquidia Technologies’ higher probable upside, research analysts clearly believe Liquidia Technologies is more favorable than Calmare Therapeutics.
Institutional & Insider Ownership
56.4% of Liquidia Technologies shares are owned by institutional investors. 4.3% of Liquidia Technologies shares are owned by insiders. Comparatively, 17.5% of Calmare Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Liquidia Technologies and Calmare Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Liquidia Technologies | N/A | -158.95% | -71.27% |
| Calmare Therapeutics | N/A | N/A | N/A |
Volatility & Risk
Liquidia Technologies has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Calmare Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500.
Valuation & Earnings
This table compares Liquidia Technologies and Calmare Therapeutics’ revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Liquidia Technologies | $2.71 million | 22.93 | -$53.14 million | ($7.51) | -0.44 |
| Calmare Therapeutics | $1.11 million | 3.31 | -$3.82 million | N/A | N/A |
Calmare Therapeutics has lower revenue, but higher earnings than Liquidia Technologies.
Summary
Liquidia Technologies beats Calmare Therapeutics on 6 of the 10 factors compared between the two stocks.
Liquidia Technologies Company Profile
Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase 1 clinical trials for the treatment of local post-operative pain. It has collaboration agreements with GlaxoSmithKline plc and the University of North Carolina. Liquidia Technologies, Inc. was founded in 2004 and is headquartered in Morrisville, North Carolina.
Calmare Therapeutics Company Profile
Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.
Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with .